Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock Price Down 1.8%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) shares traded down 1.8% during mid-day trading on Wednesday . The company traded as low as $0.80 and last traded at $0.81. 1,251 shares were traded during mid-day trading, a decline of 87% from the average session volume of 9,554 shares. The stock had previously closed at $0.83.

Eloxx Pharmaceuticals Stock Performance

The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.15. The firm has a market cap of $2.54 million, a price-to-earnings ratio of -0.09 and a beta of 2.75.

Hedge Funds Weigh In On Eloxx Pharmaceuticals

An institutional investor recently bought a new position in Eloxx Pharmaceuticals stock. Armistice Capital LLC bought a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 275,000 shares of the company’s stock, valued at approximately $1,323,000. Armistice Capital LLC owned approximately 10.00% of Eloxx Pharmaceuticals as of its most recent SEC filing. 2.90% of the stock is owned by institutional investors and hedge funds.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.